The Medical Letter on Drugs and Therapeutics
Empagliflozin (Jardiance) for Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Empagliflozin (Jardiance – Boehringer Ingelheim/Lilly), an SGLT2 inhibitor, has been approved by the FDA for oral treatment of type 2 diabetes. It is the third SGLT2 inhibitor to be approved for this indication.1,2

MECHANISM OF ACTION — SGLT2 (sodium-glucose co-transporter 2), a membrane protein expressed mainly in the kidney, transports filtered glucose from the proximal renal tubule into tubular epithelial cells. SGLT2 inhibitors decrease renal glucose reabsorption and increase urinary glucose excretion, resulting in a reduction in blood glucose levels.

CLINICAL STUDIES — In randomized, double-blind trials in patients with type 2 diabetes, use of empagliflozin, alone and in combination with metformin, a sulfonylurea, pioglitazone, or insulin, reduced HbA1c significantly more than placebo. Treatment with empagliflozin also resulted in ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Empagliflozin (Jardiance) for Diabetes
Article code: 1453b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian